Study on Ifinatamab Deruxtecan (I-DXd) for Treating Metastatic Prostate Cancer
Sponsor: Merck Sharp & Dohme LLC
ClinicalTrials ID:NCT06925737
This clinical trial is testing a new medication, Ifinatamab Deruxtecan (I-DXd), to see if it can help people with metastatic castration-resistant prostate cancer (mCRPC) live longer and prevent the cancer from growing or spreading compared to standard chemotherapy.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Researchers are exploring a new treatment option for metastatic castration-resistant prostate cancer (mCRPC) using a study drug called Ifinatamab Deruxtecan (I-DXd). The aim is to determine if I-DXd can help patients live longer and delay the progression of their cancer compared to those receiving traditional chemotherapy.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with metastatic castration-resistant prostate cancer (mCRPC).
- Cancer has progressed while on hormone therapy (or after surgical removal of the testicles) within the last 6 months.
- Previously treated with 1 or 2 androgen receptor pathway inhibitors and the cancer progressed during or after at least 8 weeks of treatment.
Exclusion Criteria
- History of lung disease or inflammation that required steroid treatment.
- Uncontrolled or serious heart disease.
- Previously treated with a taxane-based chemotherapy for mCRPC.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Cancer and Hematology Centers of Western Michigan ( Site 0015) | 49503 | Grand Rapids | Michigan |
| St. Vincent Frontier Cancer Center-Research ( Site 0037) | 59102 | Billings | Montana |
| Blue Ridge Cancer Care ( Site 0024) | 24014 | Roanoke | Virginia |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.